All News
Filter News
Found 194 articles
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 10, 2023
6/10/2023
HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 80,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.
-
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
6/1/2023
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the pricing of an underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock.
-
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
5/31/2023
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’) today announced positive preliminary data from its ongoing Phase 2 study of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer.
-
Gamida Cell Appoints Terry Coelho as CFO
5/22/2023
Gamida Cell Ltd. today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.
-
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
5/11/2023
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and business highlights for the first quarter of 2023.
-
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
5/9/2023
HOOKIPA Pharma Inc. announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400, an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead.
-
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
5/4/2023
HOOKIPA Pharma Inc. today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.
-
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May - May 4, 2023
5/4/2023
HOOKIPA Pharma Inc. today announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences.
-
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
4/26/2023
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’) today announced that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023.
-
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
4/19/2023
HOOKIPA Pharma Inc. announced that the company will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference being held in Amsterdam, April 25 - 26, 2023.
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2023
4/14/2023
HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to a new employee to purchase an aggregate of 50,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.
-
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
3/15/2023
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023.
-
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
3/13/2023
HOOKIPA Pharma Inc. announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023.
-
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors
3/9/2023
Abata Therapeutics today announced the appointment of David Kaufman, M.D., Ph.D., partner at Third Rock Ventures, to its board of directors.
-
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
3/8/2023
HOOKIPA Pharma Inc. today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023.
-
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
2/7/2023
HOOKIPA Pharma Inc. today announced that the company will participate in the virtual SVB Securities Global Biopharma Conference, February 14 - 16, 2023.
-
KRAS Inhibitor Drug LUMAKRAS Sotorasib Krazati Adagrasib Market Forecast 2029
2/3/2023
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
-
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
1/4/2023
HOOKIPA Pharma Inc., a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with Gilead Sciences, Inc.
-
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
12/15/2022
HOOKIPA Pharma Inc. announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023.
-
Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.